Our Pricing

Wegovy Pricing Guide: Real Weight Loss Results Evidence

Published on: June 03, 2026

Searching for transparent wegovy price uk weight loss results information? At Cured Pharmacy, Wegovy (semaglutide) starts from £79.00 with upfront pricing, backed by clinical trial evidence showing significant weight reduction in UK-licensed treatment programmes. Our UK-registered prescribers provide free online consultations, ensuring you receive genuine medication with complete clinical oversight.

Wegovy Price UK: What You'll Actually Pay

At Cured Pharmacy, Wegovy starts from £79.00 per dose, with transparent pricing displayed before your free clinical consultation. Unlike many providers who hide costs until after assessment, we guarantee the lowest prices in the UK with no hidden fees for prescriber consultations or delivery.

Your final cost depends on the dose prescribed by your UK clinician, which is determined through a comprehensive medical assessment. All Wegovy prescriptions require clinical approval from our GPhC-registered team, led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073). Prices include the medication, prescriber review, and discreet next-day delivery across the UK.

Clinical Evidence: STEP Trial Weight Loss Results

The STEP clinical trial programme provides the most robust evidence for Wegovy's efficacy in weight management. In the landmark STEP 1 trial, participants using semaglutide 2.4mg achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. This represents approximately 15.3kg weight loss for a 100kg individual.

STEP 2 specifically examined patients with type 2 diabetes, demonstrating an average 9.6% weight reduction alongside improved glycaemic control [2]. Importantly, 86.4% of participants in STEP 1 achieved at least 5% weight loss—the clinical threshold associated with significant health improvements—whilst 69.1% achieved 10% or greater reduction [1].

These results reflect intention-to-treat analysis, meaning they account for all participants including those who discontinued treatment. Real-world UK data suggests similar outcomes when patients maintain consistent dosing schedules under medical supervision.

Long-Term Weight Maintenance Evidence

The STEP 4 trial examined weight maintenance after initial loss, finding that patients who continued semaglutide maintained an average 17.4% total weight reduction from baseline, whilst those switched to placebo regained 6.9% [3]. This demonstrates semaglutide's role in sustained weight management rather than short-term loss alone.

How Wegovy Works: Semaglutide Mechanism

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA for chronic weight management. Semaglutide mimics the natural GLP-1 hormone, which regulates appetite through multiple pathways in the brain and digestive system [4].

The medication works by slowing gastric emptying, reducing appetite signals in the hypothalamus, and enhancing feelings of fullness after meals. Unlike stimulant-based appetite suppressants, semaglutide doesn't artificially speed metabolism—it works with your body's existing regulatory systems to normalise eating patterns and portion sizes.

Wegovy is administered as a once-weekly subcutaneous injection, with doses gradually increased over 16-20 weeks to minimise gastrointestinal side effects. The standard maintenance dose is 2.4mg weekly, though your UK prescriber may adjust this based on your response and tolerability.

Who Can Use Wegovy in the UK

NICE guidelines support GLP-1 receptor agonist use for adults with a BMI of 30 kg/m² or above, or 27 kg/m² with weight-related comorbidities such as hypertension or type 2 diabetes [5]. Your prescriber will assess your medical history, current medications, and weight loss goals during the online consultation to determine suitability. Wegovy is not appropriate for patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Wegovy vs Other Weight Loss Treatments

Several prescription weight loss medications are licensed in the UK, each with distinct mechanisms and clinical profiles. Wegovy (semaglutide) represents the current gold standard for injectable GLP-1 therapy, whilst newer dual-agonist treatments show even greater efficacy in head-to-head trials.

Saxenda contains liraglutide, an earlier GLP-1 agonist requiring daily injections rather than weekly dosing. Clinical trials show average weight loss of 8-9% with liraglutide compared to 15% with semaglutide, though daily dosing may suit patients preferring more frequent medication adjustments [6].

Orlistat (Xenical) works through a completely different mechanism—blocking dietary fat absorption in the intestine. Whilst effective for some patients, average weight loss is typically 5-7%, lower than GLP-1 treatments, with gastrointestinal side effects that can affect adherence. Your UK prescriber will discuss which option aligns best with your medical profile and lifestyle preferences.

Starting Wegovy: Dosing Schedule and Timeline

Wegovy follows a structured dose escalation protocol designed to improve tolerability whilst optimising weight loss outcomes. Treatment begins with 0.25mg weekly for four weeks, then increases every four weeks through 0.5mg, 1mg, and 1.7mg before reaching the maintenance dose of 2.4mg at week 17 [7].

This gradual titration significantly reduces the risk of nausea, vomiting, and other gastrointestinal effects commonly associated with GLP-1 therapies. Clinical data shows most patients tolerate the escalation well when following the prescribed schedule without skipping doses or accelerating increases.

Meaningful weight loss typically becomes apparent within 8-12 weeks, with continued reduction throughout the first year of treatment. NICE recommends reviewing treatment at 6 months—if you haven't achieved at least 5% weight loss by this point, your prescriber may discuss alternative approaches or investigate barriers to response [5].

What to Expect in Your First Month

During the initial 0.25mg and 0.5mg doses, you may notice reduced appetite and earlier satiety at meals, though significant weight changes are uncommon at these starter doses. Mild nausea affects approximately 20-30% of patients but typically resolves within days as your body adjusts. Staying well-hydrated, eating smaller portions, and avoiding high-fat meals can minimise early side effects.

Getting Wegovy from Cured Pharmacy: The Process

Starting treatment at Cured Pharmacy takes under three minutes with our streamlined online consultation. You'll complete a comprehensive medical questionnaire covering your weight history, current medications, and relevant health conditions. This information is reviewed by our UK-registered prescribers who determine whether Wegovy is clinically appropriate for you.

If approved, your prescription is dispensed by our GPhC-registered pharmacy (registration number 9012511) and dispatched in 100% discreet packaging with next-day delivery across the UK. Every Wegovy pen is UK-licensed and sourced through legitimate pharmaceutical supply chains—we never supply unlicensed or compounded alternatives.

Ongoing clinical support is included with every prescription. Our team monitors your progress through follow-up assessments, adjusts dosing as needed, and provides guidance on managing side effects or optimising results. You can contact our pharmacists at (+44) 116 4646009 during business hours for any clinical questions.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Davies, M., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
3. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
4. Müller, T. D., et al. (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 30, 72–130. https://doi.org/10.1016/j.molmet.2019.09.010 [accessed 13 August 2026]
5. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE. https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
6. Pi-Sunyer, X., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(11), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
7. Electronic Medicines Compendium. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen - Summary of Product Characteristics. Medicines.org.uk. https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
8. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
9. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
10. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on adherence to prescribed treatment, dietary modifications, and physical activity levels. Clinical trial data represents average outcomes and may not reflect individual experiences.